AGP Executive Report
Last update: 42 minutes agoCancer Care: The FDA approved atezolizumab with chemotherapy for stage III dMMR colon cancer. In multiple myeloma, the iberdomide triplet more than doubled median progression-free survival versus standard therapy in a phase 3 trial. New Treatment Options: The FDA also cleared remibrutinib for symptomatic dermographism and approved a Tukysa combination as maintenance therapy for HER2-positive metastatic breast cancer. Heart Failure: An FDA-cleared CardioMEMS update lets patients view pressure readings on their phones. Prescribing Oversight: A Cochrane review found pharma gifts and payments were linked to more inappropriate and costly prescribing. India’s Supreme Court ordered a panel to recommend rules on industry freebies to doctors. Drug Pricing: PhRMA sued to block Medicare’s GLOBE model, which would tie rebates for some Part B drugs to prices in 19 countries.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.